The U.S. Food and Drug Administration (FDA) announced on April 24 that Abbott has removed the HeartMate Mobile Power Unit, used with HeartMate II and HeartMate 3 Left Ventricular Assist Systems, due to reports of sudden, unexpected power loss.

According to the agency, "Abbott has identified that these issues are linked to an electrical component used to manufacture certain [mobile power units] distributed between April 2024 and February 2025."

Access recommended actions for health care providers and additional company resources on the FDA website.

Keywords: United States Food and Drug Administration, Heart Ventricles, Health Personnel, ACC Advocacy